Fluidigm (NASDAQ:FLDM)‘s stock had its “hold” rating reiterated by analysts at Piper Jaffray Companies in a research report issued on Thursday. They currently have a $6.10 price objective on the medical research company’s stock. Piper Jaffray Companies’ target price suggests a potential downside of 7.29% from the company’s current price.

Separately, ValuEngine upgraded Fluidigm from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd.

Shares of Fluidigm (FLDM) opened at $6.58 on Thursday. Fluidigm has a 52-week low of $2.52 and a 52-week high of $7.05. The company has a debt-to-equity ratio of 5.00, a quick ratio of 2.46 and a current ratio of 3.02. The stock has a market capitalization of $224.15, a P/E ratio of -2.94 and a beta of 3.24.

Fluidigm (NASDAQ:FLDM) last issued its quarterly earnings data on Thursday, February 8th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). Fluidigm had a negative net margin of 68.27% and a negative return on equity of 134.35%. The company had revenue of $27.75 million for the quarter, compared to analysts’ expectations of $27.14 million. During the same quarter last year, the company earned ($0.32) earnings per share. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. equities research analysts predict that Fluidigm will post -1.4 EPS for the current year.

In other Fluidigm news, insider Levin Capital Strategies, L.P. purchased 20,380 shares of Fluidigm stock in a transaction dated Wednesday, November 29th. The shares were purchased at an average cost of $5.71 per share, for a total transaction of $116,369.80. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders bought 482,624 shares of company stock worth $2,917,895. Company insiders own 4.70% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Virtu KCG Holdings LLC purchased a new stake in shares of Fluidigm in the second quarter worth approximately $105,000. Sei Investments Co. raised its holdings in shares of Fluidigm by 221.7% in the third quarter. Sei Investments Co. now owns 21,668 shares of the medical research company’s stock worth $109,000 after buying an additional 14,932 shares during the period. Group One Trading L.P. raised its holdings in shares of Fluidigm by 336.9% in the third quarter. Group One Trading L.P. now owns 23,155 shares of the medical research company’s stock worth $117,000 after buying an additional 17,855 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Fluidigm in the third quarter worth approximately $123,000. Finally, Alliancebernstein L.P. raised its holdings in shares of Fluidigm by 18.4% in the second quarter. Alliancebernstein L.P. now owns 45,700 shares of the medical research company’s stock worth $185,000 after buying an additional 7,100 shares during the period. Hedge funds and other institutional investors own 93.83% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Fluidigm (FLDM) Receives “Hold” Rating from Piper Jaffray Companies” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/fluidigm-fldm-receives-hold-rating-from-piper-jaffray-companies/1856575.html.

About Fluidigm

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.